Drugs / Immuncell-LC
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03983967 | Jan 2019 → Sep 2021 | — | GC Cell Corporation | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02856815 | May 2018 → Aug 2020 | hepatocellular carcinoma | GC Cell Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03220984 | Mar 2017 → Mar 2019 | colorectal cancer | Gangnam Severance Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01897610 | Dec 2013 → Jul 2017 | hepatocellular carcinoma | GC Cell Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00965718 | Sep 2009 → Dec 2010 | malignant pancreatic neoplasm | GC Cell Corporation | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04969731 | Sep 2021 → Dec 2026 expected | pancreatic ductal adenocarcinoma | GC Cell Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT00807027 | Dec 2008 → Oct 2012 | glioblastoma | GC Cell Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00699816 | Jul 2008 → Nov 2012 | hepatocellular carcinoma | GC Cell Corporation | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05053295 | Jul 2021 → Jul 2023 | adenocarcinoma, gastroesophageal cancer | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT01802138 | Feb 2013 → Jun 2016 | neuroblastoma | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immuncell-LC | “Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte ("Immuncell-LC") cell therapy in Gemcitabine refractory advanced pancreatic cancer” NCT00965718 ↗ |
| Known as | Activated T lymphocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01802138 ↗ |
| Modality | Cell therapy | “activated cytokine-induced killer (CIK) cells” PMID 25747273 ↗ Mar 2015 |
| Route | Intravenous | “administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously” NCT00807027 ↗ |